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The in vitro activities of 39 antimicrobial agents were assessed versus 74 clinical isolates of Branhamella
catarrhalis. Resistance was observed only with penicillin and ampicillin and then only with I-lactamase-
producing strains. The results of in vitro susceptibility tests with agar dilution and broth microdilution
procedures were found to be comparable. The results of broth tube macrodilution tests were, in general, one
twofold-concentration increment higher.
Branhamella catarrhalis is recognized as an etiologic
agent of a variety of infectious diseases in humans (3). In
terms of incidence and perhaps morbidity, the most impor-
tant of these are acute otitis media, maxillary sinusitis, and
bronchopulmonary infections. Numerous different oral and
parenteral antimicrobial agents may be used to treat these
diseases. The intent of this investigation was to compare the
in vitro activities of selected antimicrobial agents that are of
potential value in the treatment of Branhamella infections.
In addition, the effect of susceptibility test format on MICs
obtained with B. catarrhalis was assessed.
A total of 39 agents (Table 1) were examined versus 74
recent clinical isolates of B. catarrhalis. Among these 74
strains, 58 (78.4%) produced ,-lactamase when tested with a
conventional tube nitrocefin P-lactamase assay (7, 10). MICs
for each organism-antimicrobial combination were deter-
mined by use of an agar dilution procedure which employed
unsupplemented Mueller-Hinton agar (pH 7.2) with an inoc-
ulum size of 104 CFU per spot. Antimicrobial agents, ob-
tained from manufacturers as laboratory-grade powders,
were tested over a range of twofold-concentration incre-
ments from 0.004 to 128 ug/mnl. A growth control plate
containing no antimicrobial agent was included with each
test. Plates were incubated at 356C in ambient air for 20 to 24
h and examined for the presence of growth. The MIC was
defined as the lowest concentration of antimicrobial agent
tested which yielded no macroscopic evidence of growth of
the test organism. Each determination was done twice on
separate days, and the results were averaged to obtain an
estimate of the MIC for each organism-antimicrobial combi-
nation. In 2,848 of the 2,885 paired determinations (98.7%),
replicate MICs were the same. In no case did the results of
replicate MICs vary by more than fourfold. In cases in which
replicate MICs varied by one twofold-concentration incre-
ment, the higher value was assigned as the MIC. Depending
on the antimicrobial agent being tested, Staphylococcus
aureus ATCC 29213 or Escherichia coli ATCC 25922 was
used as the daily test control.
A total of 33 strains (20 ofthem ,B-lactamase positive) were
selected from among the original 74 clinical isolates of B.
catarrhalis for additional testing with both a broth tube
macrodilution and a microdilution procedure. Eight antimi-
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crobial agents were tested (Tables 2 and 3). Cation-supple-
mented Mueller-Hinton broth and a final inoculum concen-
tration of 1 x 105 to 2 x 105 CFU/ml were used with both
procedures. The final broth volume in tube macrodilution
tests was 2.0 ml; in microdilution tests the final broth volume
was 100 [lI. With these exceptions, both broth dilution
procedures were performed as described above with agar
dilution tests.
The results of agar dilution MIC determinations are shown
in Table 1. Among the 21 beta-lactam antimicrobial agents
examined in this investigation, resistance as defined by the
National Committee for Clinical Laboratory Standards (9)
was observed only with penicillin and ampicillin, and then
only with 3-lactamase-producing strains. The f-lactamase of
B. catarrhalis appeared to abrogate, at least to some extent,
the activity of 13 of these 21 beta-lactam antimicrobial agents
(i.e., penicillin, ampicillin, carbenicillin, ticarcillin, cephalo-
thin, cefaclor, cefamandole, cefuroxime, cefonicid, cefotax-
ime, ceftizoxime, ceftriaxone, and cefixime). However, as
indicated above, resistance was observed only in the cases
of penicillin and ampicillin. With the remaining eight beta-
lactam antimicrobial agents (i.e., piperacillin, azlocillin,
mezlocillin, cephalexin, cefoxitin, moxalactam, cefopera-
zone, and ceftazidime), MICs obtained with ,-lactamase-
producing strains were essentially equivalent to those ob-
tained with strains that lacked ,-lactamase.
When the activities of beta-lactam antimicrobial agents
were compared on a weight basis, the following observations
were made. Among the seven penicillins tested, carbenicillin
was the least active; piperacillin, azlocillin, and mezlocillin
were the most active. Cefonicid was the least active of seven
first- or second-generation cephalosporins tested; cefoxitin
was the most active. Finally, among the seven broad-
spectrum cephalosporins examined in this investigation,
cefoperazone was the least active; moxalactam was conspic-
uously the most active.
The combinations of amoxicillin-clavulanate, ampicillin-
sulbactam, and ticarcillin-clavulanate were uniformly inhib-
itory at low concentrations for both ,-lactamase-positive
and -negative strains of B. catarrhalis. This is consistent
with previous observations that the B. catarrhalis 1-lac-
tamases are inhibited by clavulanate and sulbactam (4, 8).
Resistance was not observed with any of the other 15
antimicrobial agents examined in this investigation. Among
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TABLE 1. In vitro activities of 39 antimicrobial agents for 74 clinical isolates of B. catarrhalis
MIC (pLg/ml)' for strains that were:
Antimicrobial f3-Lactamase positive (n = 58) ,B-Lactamase negative (n = 16)
agenta
50% 90% Range Geometric 50% 90% Range Geometric
mean mean
Penicillin 2.0 2.0 0.015-4.0 0.74 0.007 0.03 0.004-0.06 0.008
Ampicillin 2.0 2.0 0.03-4.0 0.89 0.007 0.06 0.004-0.125 0.01
Carbenicillin 4.0 8.0 0.25-16 2.0 0.25 0.5 0.25-0.5 0.38
Ticarcillin 2.0 4.0 0.5-4.0 1.4 0.125 0.5 0.125-0.5 0.20
Piperacillin 0.25 0.5 0.125-1.0 0.25 0.125 0.5 0.125-0.5 0.23
Azlocillin 0.25 0.5 0.125-0.5 0.22 0.125 0.25 0.125-0.5 0.22
Mezlocillin 0.25 0.5 0.125-0.5 0.23 0.25 0.5 0.125-0.5 0.24
Cephalothin 4.0 8.0 1.0-8.0 4.1 1.0 1.0 0.5-1.0 0.78
Cephalexin 4.0 4.0 1.0-4.0 3.1 2.0 4.0 2.0-4.0 2.75
Cefaclor 1.0 2.0 0.125-2.0 1.0 0.125 0.5 0.125-0.5 0.25
Cefoxitin 0.25 0.5 0.125-1.0 0.23 0.125 0.25 0.125-0.25 0.18
Cefamandole 4.0 8.0 0.5-8.0 4.0 1.0 1.0 0.5-2.0 0.91
Cefuroxime 2.0 2.0 0.5-4.0 1.5 0.5 1.0 0.25-2.0 0.69
Cefonicid 4.0 8.0 0.5-16 5.4 0.5 1.0 0.5-1.0 0.66
Cefotaxime 0.5 1.0 0.06-2.0 0.38 0.06 1.0 0.03-1.0 0.16
Moxalactam 0.007 0.007 0.004-0.015 0.006 0.004 0.007 0.004-0.007 0.006
Ceftizoxime 0.25 0.5 0.007-0.5 0.14 0.03 0.25 0.004-0.25 0.05
Ceftriaxone 0.5 1.0 0.004-1.0 0.17 0.004 0.25 0.004-0.25 0.02
Cefixime 0.25 0.5 0.03-1.0 0.22 0.06 0.5 0.03-0.5 0.11
Cefoperazone 0.5 2.0 0.125-2.0 0.55 0.125 1.0 0.125-1.0 0.51
Ceftazidime 0.06 0.25 0.007-0.5 0.07 0.03 0.25 0.004-0.25 0.06
Amox-clav 0.06 0.25 0.007-0.25 0.06 0.015 0.06 0.004-0.125 0.02
Amp-sulb 0.03 0.25 0.007-0.25 0.05 0.015 0.06 0.004-0.125 0.03
Ticar-Clav 0.25 0.5 0.125-1.0 0.27 0.125 0.5 0.125-0.5 0.22
Chloramphenicol 0.5 0.5 0.125-0.5 0.48 0.5 0.5 0.25-1.0 0.50
Tetracycline 0.25 0.5 0.25-0.5 0.33 0.25 0.5 0.125-1.0 0.36
Erythromycin 0.125 0.125 0.03-0.25 0.10 0.06 0.25 0.015-1.0 0.10
Erythro-sulfa 0.06 0.125 0.015-0.125 0.05 0.06 0.125 0.015-0.125 0.05
Sulfisoxazole 2.0 4.0 1.0-8.0 2.5 2.0 4.0 0.25-4.0 2.1
TMP-SMX 0.125 0.25 0.03-0.25 0.12 0.125 0.25 0.015-0.25 0.18
Rifampin 0.03 0.03 0.007-0.06 0.02 0.03 0.03 0.007-0.25 0.03
Ciprofloxacin 0.007 0.015 0.004-0.015 0.007 0.007 0.015 0.004-0.015 0.007
Pefloxacin 0.125 0.25 0.125-0.25 0.16 0.125 0.25 0.060.25 0.16
Aztreonam 1.0 2.0 0.125-16 1.0 0.25 2.0 0.125-4.0 0.77
Imipenem 0.125 0.25 0.03-1.0 0.11 0.125 0.25 0.03-1.0 0.10
Gentamicin 0.125 0.25 0.06-0.25 0.17 0.125 0.25 0.06-0.5 0.17
Tobramycin 0.125 0.25 0.06-0.25 0.19 0.125 0.25 0.125-0.5 0.19
Amikacin 0.5 1.0 0.125-1.0 0.47 0.5 1.0 0.125-2.0 0.63
Netilmicin 0.5 0.5 0.25-0.5 0.49 0.5 0.5 0.5 0.5
a Amox-clav, Amoxicillin-clavulanate (2:1); Amp-sulb, ampicillin-sulbactam (2:1); Ticar-clav, ticarcillin-clavulanate tested with a 2.0-pg/ml fixed concentration
of clavulanate with various concentrations of ticarcillin; Erythro-sulfa, erythromycin-sulfisoxazole (1:64); TMP-SMX, trimethoprim-sulfamethoxazole (1:19). In
all cases, the concentrations listed in the table are the concentrations of the first antimicrobial agent of the combination.
b 50% and 90%, MIC for 50 and 90% of strains tested, respectively.
these 15 agents, however, several patterns of activity were
noted. The combination of erythromycin and sulfisoxazole
was essentially comparable to either agent when tested
alone. Ciprofloxacin demonstrated considerably greater ac-
tivity than did pefloxacin. Similarly, imipenem was more
active than aztreonam. Finally, among the four aminoglyco-
sides tested, gentamicin and tobramycin were significantly
more active than amikacin and netilmicin.
Tables 2 and 3 show comparisons of the results of agar
dilution MIC determinations versus the results of broth
microdilution and tube macrodilution procedures, respec-
tively. In general, there was little difference between MICs
obtained with eight antimicrobial agents when they were
tested in the broth microdilution and agar dilution formats
(Table 2). In contrast, MICs obtained with the broth tube
macrodilution procedure were, in general, approximately
one twofold-concentration increment higher than those ob-
tained by using the agar dilution method (Table 3).
The eight antimicrobial agents selected for these compar-
TABLE 2. Comparison between results of broth microdilution
and agar dilution MIC determinations with
33 strains of B. catarrhalis
No. of strains with indicated ratio of broth
Antimicrobial microdilution MIC (log2) to agar
agent' dilution MIC (log2):
-3 -2 -1 0 +1 +2 +3
Ampicillin 1 3 24 3 1 1
Chloramphenicol 2 5 20 2 3 1
Cephalothin 2 1 1 26 1 1 1
Cefaclor 1 4 25 2 1
Tetracycline 4 22 2 4 1
Erythromycin 2 1 3 25 2
TMP-SMX 4 6 19 3 1
Amox-clav 1 1 30 1
aTMP-SMX, Trimethoprim-sulfamethoxazole (1:19); Amox-clav, amoxi-
cillin-clavulanate (2:1).
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TABLE 3. Comparison between results of broth tube
macrodilution and agar dilution MIC determinations
with 33 strains of B. catarrhalis
No. of strains with indicated ratio of broth tube
Antimicrobial macrodilution MIC (log2) to agar
agenta dilution MIC (log2):
-2 -1 0 +1 +2 +3 +4
Ampicillin 1 1 4 19 6 1 1
Chloramphenicol 1 1 3 26 2
Cephalothin 1 1 7 21 2 1
Cefaclor 1 1 9 17 5
Tetracycline 1 4 14 13 1
Erythromycin 1 1 4 23 4
TMP-SMX 1 2 3 13 9 3 2
Amox-clav 1 6 22 3 1
a TMP-SMX, Trimethoprim-sulfamethoxazole (1:19); Amox-clav, amoxi-
cillin-clavulanate (2:1).
isons were the same as those used in a previous study aimed
at defining zone diameter interpretive criteria for disk diffu-
sion susceptibility tests with B. catarrhalis (6). The results of
broth tube macrodilution MIC determinations in that study
were essentially identical to those obtained with this method
in the present investigation.
The results of this study emphasize several important
points concerning the activities of selected antimicrobial
agents versus B. catarrhalis. The in vitro activities of
beta-lactam compounds for this organism vary greatly, de-
pending on the agent. In addition, the inhibitory effect of the
1-lactamases of B. catarrhalis on the activity of beta-lactam
antimicrobial agents is variable. However, it remains that,
with the exceptions of penicillin and ampicillin, resistance
was not noted with any of the beta-lactam antimicrobial
agents examined in this investigation with either ,-lacta-
mase-positive or -negative strains. The results of this inves-
tigation also corroborate and extend previous observations
that numerous other antimicrobial agents have extensive in
vitro activity for B. catarrhalis (1, 2, 4, 11). These include a
variety of oral and parenteral agents.
Finally, it should be noted that the results of quantitative
susceptibility tests with B. catarrhalis are influenced by test
format. In general, MICs obtained using agar dilution tests
with an inoculum of ca. 104 CFU per spot are equivalent to
MICs determined using broth microdilution procedures with
an inoculum of ca. 105 CFU/ml. In contrast, MICs obtained
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with the broth tube macrodilution technique using an inocu-
lum size of ca. 105 CFU/ml are one twofold-concentration
increment higher. This is perhaps explained by the 10-fold-
higher number of organisms exposed to antimicrobial agent
in the tube macrodilution format, since the inoculum effect is
known to influence the results of quantitative in vitro sus-
ceptibility tests with B. catarrhalis (5).
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